Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray
Go back to Aptar’s Intranasal Delivery System Used in Phase II Clinical Study for Investigational SPONTAN® Nasal Spray| APTARGROUP, Inc. (NYSE: ATR) | Delayed: 126.01 +0.81 (0.65%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $125.20 | 52 Week High | $81.50 | |||
| Open | $125.12 | 52 Week Low | $66.33 | |||
| Day High | $126.84 | P/E | 50.00 | |||
| Day Low | $124.10 | EPS | $2.52 | |||
| Volume | 107,398 | |||||
